Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
MaxCyte ( (MXCT) ) has issued an update.
MaxCyte, Inc., a company involved in the biotechnology industry, has announced a change in its major shareholders as BlackRock, Inc. has increased its stake. As of February 12, 2025, BlackRock now holds 7.66% of voting rights in MaxCyte, up from a previous 7.64%, indicating a slight increase in their influence over company decisions. This adjustment in shareholding could have implications for MaxCyte’s strategic directions and governance, potentially impacting its market positioning and operational strategy moving forward.
More about MaxCyte
YTD Price Performance: 2.47%
Average Trading Volume: 52,173
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £355.7M
See more data about MXCT stock on TipRanks’ Stock Analysis page.
